Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, May 3rd. Analysts expect the company to announce earnings of ($1.00) per share for the quarter. Ionis Pharmaceuticals has set its FY 2023 guidance at EPS.Individual interested in participating in the company’s earnings conference call […]
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) has been assigned an average recommendation of “Hold” from the fourteen brokerages that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and five have issued a buy recommendation on the […]
AtonRa Partners reduced its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 21.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,875 shares of the company’s stock after selling 3,753 shares during the period. AtonRa Partners’ holdings in […]
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) traded down 3.9% during trading on Tuesday . The company traded as low as $36.23 and last traded at $36.31. 249,701 shares were traded during trading, a decline of 74% from the average session volume of 942,465 shares. The stock had previously closed at $37.78. Wall Street Analyst […]
Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating) had its target price boosted by Morgan Stanley from $40.00 to $42.00 in a report released on Tuesday morning, Benzinga reports. Morgan Stanley currently has an equal weight rating on the stock. A number of other brokerages also recently weighed in on IONS. Needham & Company LLC reiterated a […]